Comparing the current results to its competitors, Exact Sciences reported Revenue increase in the 4 quarter 2025 by 23.12 % year on year. The sales growth was above Exact Sciences's competitors' average revenue growth of 15.54 %, achieved in the same quarter.
Exact Sciences's Comment on Competition and Industry Peers
The company operates in a competitive industry with numerous private and public companies offering or developing similar products. Competition is expected to increase as established and emerging companies introduce new tests and technologies, sometimes supported by larger companies with greater resources or brand recognition. Key competitive factors include test performance, reimbursement and payer coverage, ease of use, product value, sales and marketing effectiveness, distribution breadth, and reputation. In the U.S. colorectal cancer screening market, the company's Cologuard and Cologuard Plus tests compete with procedure-based detection technologies such as colonoscopy, flexible sigmoidoscopy, virtual colonoscopy, stool-based tests including fecal occult blood test and fecal immunochemical test (FIT), capsule endoscopy, and Geneoscopy, Inc.'s ColoSense test, which has received FDA approval.
October 4, 2024
A New Era in Colorectal Cancer Screening: The FDA s Approval of Exact Sciences Cologuard Plus In a landmark decision, the U.S. Food and Drug Administration (FDA) has bestowed its approval upon Exact Sciences Corp. s newest innovation, the Cologuard Plus test. This FDA endorsement marks a significant milestone in the evolution of non-invasive colorectal cancer screenings. Exact Sciences Corporation, a vanguard in cancer screening and diagnostic innovation, has once again drawn the spotlight with this next-generation multitarget stool DNA test, made available for adults aged 45 and older who are at average risk for colorectal cancer.The approval of Cologuard Plus was underpinned by the pivotal BLUE-C study, o...
May 27, 2024
MADISON, Wisconsin - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer early detection and diagnostic tests, will present 10 abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June 4, 2024, in Chicago, Illinois. These abstracts will showcase the breadth and depth of the company s early detection and diagnostic portfolio, presenting new data that demonstrate both predictive and prognostic capabilities.Exact Sciences has consistently positioned itself as a forerunner in the field of cancer early detection, continuously striving to improve treatment outcomes. The company s participation in the prestigious ASCO Annual Meeting solidifies its c...
May 21, 2024
In a significant development for the healthcare and biotechnology sectors, leading cancer screening and diagnostic test provider, Exact Sciences Corp., has been granted permission to proceed with a patent infringement lawsuit against Geneoscopy. The recent ruling by a U.S. District Court judge in the District of Delaware denies in part Geneoscopy s motion to dismiss the case, providing Exact Sciences with an opportunity to seek redress for Geneoscopy s alleged future infringement and false advertising. This landmark decision has the potential to shape the future of cancer screening, offering patients more accurate detection and diagnostic methods, and could have wider implications for the entire industry.Und...
Publicly Traded Peers of Exact Sciences Corporation
Genedx Holdings Corp Share Performance
+62.18%
This Quarter
Genedx Holdings Corp
Profile
Genedx Holdings Corp operates as a genetic testing company, offering molecular and biochemical testing services for various genetic disorders and diseases. The company generates revenue by providing testing services to medical professionals and institutions around the world, aiding in accurate diagnosis and treatment planning for patients.
Mainz Biomed N v operates on a business model focused on the development and commercialization of innovative biomedical solutions. They leverage their expertise in research, development, and manufacturing to create novel biopharmaceutical products with strong market potential. Through strategic partnerships and collaborations, they aim to bring their cutting-edge products to the market, ultimately improving healthcare outcomes.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Motus Gi Holdings Inc operates as a medical technology company that designs, develops, and commercializes innovative solutions for gastrointestinal endoscopy procedures. Their business model is centered around providing healthcare professionals with advanced imaging and therapeutic technologies to improve patient outcomes and enhance procedural efficiency.
MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.
Sources:
Exact Sciences Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Exact Sciences Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
